"Prevention of sarcopenia slows the progress of Parkinson's disease."
Sep 24, 2024
Professor Heo Young-eun of neurology at Cha Medical University Bundang Cha Hospital (Director Yoon Sang-wook) revealed that sarcopenia is an important cause of drug-induced dyskinesia in Parkinson's disease patients. The study was published in the recent issue of the international journal `NPJ Parkinson's Disease (IF=7.0).'
Sarcopenia is a disease that reduces muscle mass and reduces muscle function, and is known to be the cause of various diseases such as falls, dementia, and diabetes, and its importance has recently been highlighted. The association between sarcopenia and Parkinson's disease has also been raised, but no clear causal relationship has been identified so far due to the limitations of traditional observational epidemiological studies that are vulnerable to confounding and reverse causation (a situation in which causes and effects are reversed).
Professor Heo Young-eun's team introduced a Mendel random analysis method to overcome these limitations. Mendel random analysis is a research method that uses genetic variation as an instrumental variable to derive a causal relationship between risk factors and diseases while excluding confounding factors and inverse causal relationships.
Using genome-wide association study data based on large cohorts such as UK biobank, the research team confirmed that the decrease in grip strength and muscle mass reflecting sarcopenia significantly increased the risk of Parkinson's disease progression, especially drug-induced dyskinesia. It was also confirmed that a forward causal relationship was established between them. Through polygenic scores and path enrichment analysis, synaptic plasticity is a key mechanism to explain the causal correlation between them.
Parkinson's disease is a disease that has no treatment to fundamentally prevent the occurrence and progression of the disease, and this study suggests that sarcopenia is a new treatment target to slow the progression of Parkinson's disease.
Professor Heo Young-eun said, "A meaningful study has suggested a new treatment target for Parkinson's disease, in which there is no treatment to prevent the cause and progression of the disease. Drug-induced dyskinesia is a long-term complication that occurs during Parkinson's disease treatment and most Parkinson's disease patients suffer, and prevention and treatment are important." "We expect that the development of drug treatments to alleviate sarcopenia, including strength training to improve sarcopenia, sufficient high-quality protein intake, leucine and vitamin D supplementation, will be a new treatment to delay the progression of Parkinson's disease," he said.
The study was conducted in collaboration with an AI team at Northwestern Polytechnic University in China.
Meanwhile, Bundang Cha Hospital opened the Parkinson's Disease Center in 2023 and provides patient-specific treatment focusing on neurorenewal treatment and exercise treatment.
Sarcopenia is a disease that reduces muscle mass and reduces muscle function, and is known to be the cause of various diseases such as falls, dementia, and diabetes, and its importance has recently been highlighted. The association between sarcopenia and Parkinson's disease has also been raised, but no clear causal relationship has been identified so far due to the limitations of traditional observational epidemiological studies that are vulnerable to confounding and reverse causation (a situation in which causes and effects are reversed).
Professor Heo Young-eun's team introduced a Mendel random analysis method to overcome these limitations. Mendel random analysis is a research method that uses genetic variation as an instrumental variable to derive a causal relationship between risk factors and diseases while excluding confounding factors and inverse causal relationships.
Using genome-wide association study data based on large cohorts such as UK biobank, the research team confirmed that the decrease in grip strength and muscle mass reflecting sarcopenia significantly increased the risk of Parkinson's disease progression, especially drug-induced dyskinesia. It was also confirmed that a forward causal relationship was established between them. Through polygenic scores and path enrichment analysis, synaptic plasticity is a key mechanism to explain the causal correlation between them.
Parkinson's disease is a disease that has no treatment to fundamentally prevent the occurrence and progression of the disease, and this study suggests that sarcopenia is a new treatment target to slow the progression of Parkinson's disease.
Professor Heo Young-eun said, "A meaningful study has suggested a new treatment target for Parkinson's disease, in which there is no treatment to prevent the cause and progression of the disease. Drug-induced dyskinesia is a long-term complication that occurs during Parkinson's disease treatment and most Parkinson's disease patients suffer, and prevention and treatment are important." "We expect that the development of drug treatments to alleviate sarcopenia, including strength training to improve sarcopenia, sufficient high-quality protein intake, leucine and vitamin D supplementation, will be a new treatment to delay the progression of Parkinson's disease," he said.
The study was conducted in collaboration with an AI team at Northwestern Polytechnic University in China.
Meanwhile, Bundang Cha Hospital opened the Parkinson's Disease Center in 2023 and provides patient-specific treatment focusing on neurorenewal treatment and exercise treatment.
|
bellho@sportschosun.com
